About: Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Aims: A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment. Methods: A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and { 90%). Reduced RDI in two groups (90-99% and { 90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared. Results: Multivariate analysis showed here were no significant differences in probability of CR (HR 0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17; HR 1.54, 95% CI [0.91-2.6], P=0.22) or OS (mean 15 vs. 13 vs. 14 years, P=0.13; HR 1.52, 95% CI [0.93-2.5], P=0.13). Conclusion: We found no significant impact of primary chemotherapy delay resulting in reduced RDI on outcome in HL patients.
  • Aims: A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment. Methods: A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and { 90%). Reduced RDI in two groups (90-99% and { 90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared. Results: Multivariate analysis showed here were no significant differences in probability of CR (HR 0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17; HR 1.54, 95% CI [0.91-2.6], P=0.22) or OS (mean 15 vs. 13 vs. 14 years, P=0.13; HR 1.52, 95% CI [0.93-2.5], P=0.13). Conclusion: We found no significant impact of primary chemotherapy delay resulting in reduced RDI on outcome in HL patients. (en)
Title
  • Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma
  • Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma (en)
skos:prefLabel
  • Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma
  • Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma (en)
skos:notation
  • RIV/61989592:15110/14:33144644!RIV15-MSM-15110___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • P(EE2.3.20.0170), S, Z(MSM6198959205)
http://linked.open...iv/cisloPeriodika
  • 3
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 41701
http://linked.open...ai/riv/idVysledku
  • RIV/61989592:15110/14:33144644
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • therapeutic outcome; relative dose intensity; chemotherapy; primary treatment; Hodgkin lymphoma (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • CZ - Česká republika
http://linked.open...ontrolniKodProRIV
  • [65B608A3F1C6]
http://linked.open...i/riv/nazevZdroje
  • Biomedical Papers-Olomouc
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 158
http://linked.open...iv/tvurceVysledku
  • Faber, Edgar
  • Indrák, Karel
  • Raida, Luděk
  • Rusiňáková, Zuzana
  • Tuček, Pavel
  • Procházka, Vít
  • Papajík, Tomáš
  • Mlčůchová, Dana
http://linked.open...n/vavai/riv/zamer
issn
  • 1213-8118
number of pages
http://bibframe.org/vocab/doi
  • 10.5507/bp.2013.022
http://localhost/t...ganizacniJednotka
  • 15110
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 107 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software